| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT06179888 Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple… |
Recruitment suspended |
| 2026-06-02 | NCT07601100 Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant… |
Primary endpoint(s) modified |
| 2026-06-02 | NCT07601100 Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant… |
Trial arms changed: 2 -> 6 |
| 2026-06-02 | NCT05434689 COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide |
date change Primary completion pushed: 2026-04 -> 2028-08 |
| 2026-06-02 | NCT05434689 COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide |
date change Completion pushed: 2026-10 -> 2028-08 |
| 2026-05-15 | NCT06215118 A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and… |
Trial sites expanded: 21 -> 43 locations |
| 2026-05-14 | NCT06465316 Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory… |
date change Primary completion pushed: 2026-09-16 -> 2026-12-31 |
| 2026-05-14 | NCT06465316 Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory… |
date change Completion pushed: 2026-09-16 -> 2026-12-31 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-03 | NCT07624513 Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction… | Phase 3 | Not Yet Recruiting |
| 2026-05-22 | NCT07601100 Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant… | Phase 1/2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06216158 | Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly… | Multiple Myeloma | Recruiting |
| NCT05827016 | A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy… | Multiple Myeloma | Recruiting |
| NCT04975997 | Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus… | Multiple Myeloma | Active, Not Recruiting |
| NCT07624513 | Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction… | Multiple Myeloma | Not Yet Recruiting |
| Phase 2 | |||
| NCT05896228 | Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With… | Refractory Multiple Myeloma | Recruiting |
| NCT05272826 | Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE… | Multiple Myeloma | Recruiting |
| NCT05527340 | Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in… | Multiple Myeloma | Active, Not Recruiting |
| NCT05354557 | Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous… | Multiple Myeloma | Active, Not Recruiting |
| NCT05177536 | Iberdomide Maintenance Therapy in Patients With Multiple Myeloma | Multiple Myeloma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05199311 | Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple… | Multiple Myeloma | Recruiting |
| NCT06232044 | Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With… | Recurrent Multiple Myeloma | Recruiting |
| NCT05583617 | A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With… | Multiple Myeloma | Recruiting |
| NCT02773030 | A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and… | Multiple Myeloma | Active, Not Recruiting |
| NCT07437963 | Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come… | Recurrent Ganglioneuroblastoma | Not Yet Recruiting |
| NCT05392946 | Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed… | Plasma Cell Myeloma | Active, Not Recruiting |
| NCT05434689 | COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide | Multiple Myeloma | Active, Not Recruiting |
| NCT07601100 | Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant… | Newly Diagnosed Multiple Myeloma | Not Yet Recruiting |
| Phase 1 | |||
| NCT06121843 | A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene… | Multiple Myeloma | Recruiting |
| NCT06348108 | Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory… | Multiple Myeloma | Recruiting |
| NCT06896916 | Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3… | Multiple Myeloma | Recruiting |
| NCT05169515 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or… | Non-Hodgkin Lymphoma | Recruiting |
| NCT06465316 | Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory… | Recurrent Multiple Myeloma | Recruiting |
| NCT04884035 | Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to… | Lymphoma, B-Cell | Recruiting |
| NCT06215118 | A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and… | Multiple Myeloma | Recruiting |
| Early Phase 1 | |||
| NCT05560399 | A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for… | Multiple Myeloma | Active, Not Recruiting |